• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

An Egg A Day Might Reduce Your Risk Of Heart Disease, Study Says
In this study however, they didn’t assess the risk of developing diabetes, which may be because diabetes is a newer disease in the Chinese population and there is not good documentation of who has it,” Richard said. Still, she noted, “this will be very important data for helping develop dietary prevention guidelines in China.” Cardiovascular disease, which takes the lives of 17.7 million people every year, is the leading cause of death and disability worldwide, according to the World Health Organization. Cardiovascular disease causes nearly a third — 31% — of all global deaths each year....
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 22, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Eggs Heart Disease Local TV Source Type: news

Let Plants be Thy Medicine – You Are What You Eat
Credit: Busani Bafana/IPSBy Esther Ngumbi and Ifeanyi NsoforILLINOIS, United States / ABUJA, Oct 16 2019 (IPS) United Nations World Food Day is celebrated around the world on October 16 under the theme: “Our Actions ARE Our Future. Healthy Diets for a Zero Hunger World”. This theme is timely, especially, because across Africa and around the world, there has been a gradual rise in malnutrition and diet-related non communicable diseases, as highlighted in The Lancet study and a United Nations Report published earlier this year. While 45 percent of deaths in children are from nutrition-related causes, mainly malnu...
Source: IPS Inter Press Service - Health - October 16, 2019 Category: International Medicine & Public Health Authors: Esther Ngumbi and Ifeanyi Nsofor Tags: Food & Agriculture Global Headlines Health World Food Day Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news